Back to Search
Start Over
The Evolution of Chimeric Antigen Receptor T-Cell Therapy in Children, Adolescents and Young Adults with Acute Lymphoblastic Leukemia.
- Source :
- Biomedicines; Sep2022, Vol. 10 Issue 9, p2286-2286, 21p
- Publication Year :
- 2022
-
Abstract
- Chimeric antigen receptor T-cell (CAR T) therapy is a revolutionary treatment for pediatric, adolescent and young adult patients (AYA) with relapsed/refractory B-cell acute lymphoblastic leukemia. While the landscape of immunotherapy continues to rapidly evolve, widespread use of CAR T therapy is limited and many questions remain regarding the durability of CAR T therapy, methods to avoid CAR T therapy resistance and the role of consolidative stem cell transplant. Modified strategies to develop effective and persistent CAR T cells at lower costs and decreased toxicities are warranted. In this review we present current indications, limitations and future directions of CAR T therapy for ALL in the pediatric and AYA population. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 22279059
- Volume :
- 10
- Issue :
- 9
- Database :
- Complementary Index
- Journal :
- Biomedicines
- Publication Type :
- Academic Journal
- Accession number :
- 159274782
- Full Text :
- https://doi.org/10.3390/biomedicines10092286